5,10-Methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women

American Journal of Clinical Nutrition

Volumn 75, Issue 2, 2002, Pages 275-282

  Fohr, Iris P ^a   Prinz Langenohl, Reinhild ^a   Brönstrup, Anja ^a   Bohlmann, Anja M ^b   Nau, Heinz ^b   Berthold, Heiner K ^a   Pietrzik, Klaus ^a  

^a UNIVERSITY OF BONN   (Germany)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

Folic acid; Homocysteine; Methylenetetrahydrofolate reductase; Methyltetrahydrofolate; MTHFR genotype; Supplementation; Women

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; HOMOCYSTEINE; PLACEBO;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; NEURAL TUBE DEFECT; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; VASCULAR DISEASE;

EID: 0036156638     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/75.2.275     Document Type: Article

References (48)

1. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
2. Plasma homocysteine as a risk factor for vascular disease
3. Homocysteine and cardiovascular disease
4. Maternal hyperhomocysteinemia: A risk factor for neural-tube defects?
5. Homocysteine metabolism in pregnancies complicated by neural-tube defects
6. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review
7. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: The Hordaland Homocysteine Study
8. Plasma folic acid cutoff value, derived from its relationship with homocyst(e)ine
9. Folate deficiency beyond megaloblastic anemia: Hyperhomocysteinemia and other manifestations of dysfunctional folate status
10. Folate-homocysteine interrelations: Potential new markers of folate status
11. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians
12. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations
13. Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase
14. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
15. Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease
16. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes
17. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis
18. Is the common C677T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis
19. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida
20. A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects
21. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials
22. Low-dose folic acid supplementation decreases plasma homocysteine concentrations: A randomized trial
23. Effects of folic acid and combinations of folic acid and vitamin B-12 on plasma homocysteine concentrations in healthy, young women
24. Folic acid and vitamin B6 supplementation and plasma homocysteine concentrations in healthy young women
25. Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid
26. Controlled dietary folate affects folate status in nonpregnant women
27. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects
28. Unmetabolized folic acid in serum: Acute studies in subjects consuming fortified food and supplements
29. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients
30. The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. A case-control study of patients with early-onset thrombotic events
31. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia
32. Folic acid and vitamin B12
33. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection
34. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum
35. Determination of folate patterns in mouse plasma, erythrocytes, and embryos by HPLC coupled with a microbiological assay
36. The transport of thiamine, riboflavin and pyridoxal-5′-phosphate by human placenta
37. Assay of pyridoxal-5′-phosphate, pyridoxal and pyridoxic acid in biological material
38. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease
39. Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages
40. Vitamin supplementation reduces blood homocysteine levels: A controlled trial in patients with venous thrombosis and healthy volunteers
41. Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer
42. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene
43. Results of an international round robin for serum and red cell folate
44. FLAIR intercomparison on serum and red cell folate